文献速递肿瘤 PET/CT甲状腺核医学

PRIMARY评分:利用前列腺内68Ga-PSMA PET/CT模式优化前列腺癌诊断

The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis.
PubMed 文献 · J Nucl Med · 2022-03-17

该研究为PRIMARY试验的事后分析,纳入291例疑似前列腺癌且未活检的男性,评估前列腺内68Ga-PSMA PET/CT模式并提出5分PRIMARY评分。结果显示,PRIMARY评分1-5分对应的临床显著前列腺癌比例分别为8.5%、27%、38%、76%和100%,以1-2分为低危、3-5分为高危时,敏感度88%、特异度64%、阳性预测值76%、阴性预测值81%,均高于mpMRI PI-RADS 2 vs 3-5的相应值。结论认为PRIMARY评分对临床显著前列腺癌具有高诊断准确性,但需进一步验证后方可实施。

要点

  • PRIMARY评分1-5分对应的临床显著前列腺癌比例分别为8.5%、27%、38%、76%和100%。
  • 以PRIMARY评分1-2分为低危、3-5分为高危时,敏感度88%、特异度64%、阳性预测值76%、阴性预测值81%。
  • PRIMARY评分1-2分 vs 3-5分的读者间Cohen κ为0.76(95% CI, 0.64-0.88)和0.64(95% CI, 0.49-0.78)。

核心结论

  • PRIMARY评分结合前列腺内68Ga-PSMA PET/CT模式和强度,对临床显著前列腺癌显示出高诊断准确性潜力,但实施前需进一步验证。

研究设计与样本

  • PRIMARY试验为前瞻性多中心II期影像试验,纳入疑似前列腺癌、无既往活检、近期(6个月内)接受mpMRI且计划前列腺活检的男性。
  • 本分析为PRIMARY试验的事后分析,共291例男性接受mpMRI、68Ga-PSMA PET/CT和系统活检(伴或不伴靶向活检)。
  • 68Ga-PSMA PET/CT(仅盆腔)在注射后至少60分钟采集,中央判读模式(弥漫移行区、对称中央区、局灶移行区或局灶外周区)和强度(SUVmax)。
  • 另有两名读者独立对118份扫描进行PRIMARY评分以确定读者间一致性。

主要发现

  • 291例中162例(56%)患有临床显著前列腺癌。
  • PRIMARY评分1分占16%(47例)、2分占19%(55例)、3分占10%(29例)、4分占40%(117例)、5分占15%(43例)。
  • PRIMARY评分1、2、3、4、5分患者中临床显著前列腺癌比例分别为8.5%(4/47)、27%(15/55)、38%(11/29)、76%(89/117)和100%(43/43)。
  • 以PRIMARY评分1-2分为低危、3-5分为高危时,敏感度88%、特异度64%、阳性预测值76%、阴性预测值81%;mpMRI PI-RADS 2 vs 3-5的相应值分别为83%、53%、69%和72%。
  • PRIMARY评分1-2分 vs 3-5分的Cohen κ为读者1 0.76(95% CI, 0.64-0.88)、读者2 0.64(95% CI, 0.49-0.78)。

关键数值与推荐

  • PRIMARY评分定义:无模式为1分,弥漫移行区或中央区(非局灶)为2分,局灶移行区为3分,局灶外周区为4分,SUVmax至少12为5分。
  • 临床显著前列腺癌定义为国际泌尿病理学会分级组≥2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出实施前需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has improved negative predictive value over mpMRI alone for csPCa. The aim of this post hoc analysis of the PRIMARY study was to evaluate the clinical significance of patterns of intraprostatic PSMA activity, proposing a 5-point PRIMARY score to optimize the accuracy of 68Ga-PSMA PET/CT for csPCa in a low-prevalence population. Methods: The PRIMARY trial was a prospective multicenter phase II imaging trial that enrolled men with suspected PCa, no prior biopsy, and a recent mpMRI examination (6 mo) and for whom prostate biopsy was planned. In total, 291 men underwent mpMRI, 68Ga-PSMA PET/CT, and systematic biopsy with or without targeted biopsy. The mpMRI was read separately using the Prostate Imaging Reporting and Data System (PI-RADS) (version 2). 68Ga-PSMA PET/CT (pelvis only) was acquired a minimum of 60 min after injection. 68Ga-PSMA PET/CT was centrally read for pattern (diffuse transition zone [TZ], symmetric central zone [CZ], focal TZ, or focal peripheral zone [PZ]) and intensity (SUVmax). In this post hoc analysis, a 5-level PRIMARY score was assigned on the basis of analysis of the central read: no pattern (score of 1), diffuse TZ or CZ (not focal) (score of 2), focal TZ (score of 3), focal PZ (score of 4), or an SUVmax of at least 12 (score of 5). Two further readers independently assigned a PRIMARY score to 118 scans to determine interrater agreement. Associations between PRIMARY score and csPCa (International Society of Urological Pathology grade group ≥ 2) were evaluated. Results: Of the 291 men enrolled, 162 (56%) had csPCa. A PRIMARY score of 1 was present in 16% (47); a score of 2, in 19% (55); a score of 3, in 10% (29); a score of 4 in 40% (117); and a score of 5, in 15% (43). The proportion of patients with csPCa and a PRIMARY score of 1, 2, 3, 4, and 5 was 8.5% (4/47), 27% (15/55), 38% (11/29), 76% (89/117), and 100% (43/43), respectively. Sensitivity, specificity, positive predictive value, and negative predictive value for a PRIMARY score of 1 or 2 (low-risk patterns) versus a PRIMARY score of 3-5 (high-risk patterns) were 88%, 64%, 76%, and 81%, respectively, compared with 83%, 53%, 69%, and 72%, respectively, for a PI-RADS score of 2 versus 3-5 on mpMRI. The Cohen κ for a PRIMARY score of 1 of 2 versus a PRIMARY score of 3-5 was 0.76 (95% CI, 0.64-0.88) for reader 1 and 0.64 (95% CI, 0.49-0.78) for reader 2. Conclusion: A PRIMARY score incorporating intraprostatic pattern and intensity on 68Ga-PSMA PET/CT shows potential, with high diagnostic accuracy for csPCa. Further validation is warranted before implementation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Emmett L, Papa N, Buteau J, et al. The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med. 2022. PMID: 35301240. doi:10.2967/jnumed.121.263448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。